Chemotherapy-induced Nausea and Vomiting Drugs Market Size, Share, Analysis and Forecasts To 2021
Market Research Analysts forecast the global CINV drugs market to grow at a CAGR of 5.41 % during the period 2017-2021.
According to the report, the high unmet medical need in the market has driven the R & D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn has collaborated with Taiho Pharmaceutical for the development and commercialization of netupitant IV in Japan. Heron Therapeutics is developing HTX-019, currently in Phase I stage, for the prevention and treatment of CINV. In addition, new vendors such as Shin Nippon Biomedical Laboratories and Acacia Pharma are aggressively advancing their pipeline to launch new drugs during the forecast period. Shin Nippon Biomedical Laboratories and Acacia are developing granisetron intranasal and APD403, respectively. Both these drugs are in Phase II development stage. These pipeline drugs are expected to gain approval during the forecast period and will likely fuel the market growth.
Download Sample Report @ https:// marketreportscenter. com / request-sample / 494138
Covered in this report
The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.
The market is divided into the following segments based on geography:
Americas APAC EMEA
Technavio ' s report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors GlaxoSmithKline Helsinn Heron Therapeutics Merck Tesaro